Omics-Based Clinical Trials Market Size, Share, Trends, Growth 2034

Omics-Based Clinical Trials Market

Omics-Based Clinical Trials Market By Phase Type (Phase 1, Phase II, Phase III, and Phase IV), By Study Design Type (Observational Studies, Interventional Studies, and Expanded Access Studies), By Indication Type (Genetic Diseases, Respiratory Diseases, Oncology, Immunology, CNS Diseases, Skin Diseases, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034

Category: Pharmaceutical Report Format : PDF Pages: 211 Report Code: ZMR-9461 Published Date: May-2025 Status : Published
Market Size in 2024 Market Forecast in 2034 CAGR (in %) Base Year
USD 6.46 Billion USD 13.56 Billion 7.70% 2024

Omics-Based Clinical Trials Market

Table Of Content

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market research methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Omics-Based Clinical Trials Market, (2025 - 2034) (USD Billion )
    • 2.2 Global Omics-Based Clinical Trials Market : snapshot
  • Chapter 3. Global Omics-Based Clinical Trials Market - Industry Analysis
    • 3.1 Omics-Based Clinical Trials Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Rising demand for improved cancer detection and treatment strategies to fuel market revenue
    • 3.3 Market Restraints
      • 3.3.1. Expenses associated with an initial investment to limit the industry’s expansion rate
    • 3.4 Market Opportunities
      • 3.4.1. Ongoing innovations in terms of new equipment and technologies aiding clinical trials to create growth opportunities
    • 3.5 Market Challenges
      • 3.5.1. Strict regulatory measures worldwide to impede market expansion trajectory
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market attractiveness analysis By Phase Type
      • 3.7.2 Market attractiveness analysis By Study Design Type
      • 3.7.3 Market attractiveness analysis By Indication Type
  • Chapter 4. Global Omics-Based Clinical Trials Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Omics-Based Clinical Trials Market: company market share, 2024
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Omics-Based Clinical Trials Market - Phase Type Analysis
    • 5.1 Global Omics-Based Clinical Trials Market overview: By Phase Type
      • 5.1.1 Global Omics-Based Clinical Trials Market share, By Phase Type, 2024 and 2034
    • 5.2 Phase 1
      • 5.2.1 Global Omics-Based Clinical Trials Market by Phase 1, 2025 - 2034 (USD Billion )
    • 5.3 Phase II
      • 5.3.1 Global Omics-Based Clinical Trials Market by Phase II, 2025 - 2034 (USD Billion )
    • 5.4 Phase III
      • 5.4.1 Global Omics-Based Clinical Trials Market by Phase III, 2025 - 2034 (USD Billion )
    • 5.5 Phase IV
      • 5.5.1 Global Omics-Based Clinical Trials Market by Phase IV, 2025 - 2034 (USD Billion )
  • Chapter 6. Global Omics-Based Clinical Trials Market - Study Design Type Analysis
    • 6.1 Global Omics-Based Clinical Trials Market overview: By Study Design Type
      • 6.1.1 Global Omics-Based Clinical Trials Market share, By Study Design Type, 2024 and 2034
    • 6.2 Observational Studies
      • 6.2.1 Global Omics-Based Clinical Trials Market by Observational Studies, 2025 - 2034 (USD Billion )
    • 6.3 Interventional Studies
      • 6.3.1 Global Omics-Based Clinical Trials Market by Interventional Studies, 2025 - 2034 (USD Billion )
    • 6.4 Expanded Access Studies
      • 6.4.1 Global Omics-Based Clinical Trials Market by Expanded Access Studies, 2025 - 2034 (USD Billion )
  • Chapter 7. Global Omics-Based Clinical Trials Market - Indication Type Analysis
    • 7.1 Global Omics-Based Clinical Trials Market overview: By Indication Type
      • 7.1.1 Global Omics-Based Clinical Trials Market share, By Indication Type, 2024 and 2034
    • 7.2 Genetic Diseases
      • 7.2.1 Global Omics-Based Clinical Trials Market by Genetic Diseases, 2025 - 2034 (USD Billion )
    • 7.3 Respiratory Diseases
      • 7.3.1 Global Omics-Based Clinical Trials Market by Respiratory Diseases, 2025 - 2034 (USD Billion )
    • 7.4 Oncology
      • 7.4.1 Global Omics-Based Clinical Trials Market by Oncology, 2025 - 2034 (USD Billion )
    • 7.5 Immunology
      • 7.5.1 Global Omics-Based Clinical Trials Market by Immunology, 2025 - 2034 (USD Billion )
    • 7.6 CNS Diseases
      • 7.6.1 Global Omics-Based Clinical Trials Market by CNS Diseases, 2025 - 2034 (USD Billion )
    • 7.7 Skin Diseases
      • 7.7.1 Global Omics-Based Clinical Trials Market by Skin Diseases, 2025 - 2034 (USD Billion )
    • 7.8 Others
      • 7.8.1 Global Omics-Based Clinical Trials Market by Others, 2025 - 2034 (USD Billion )
  • Chapter 8. Omics-Based Clinical Trials Market - Regional Analysis
    • 8.1 Global Omics-Based Clinical Trials Market Regional Overview
    • 8.2 Global Omics-Based Clinical Trials Market Share, by Region, 2024 & 2034 (USD Billion )
    • 8.3. North America
      • 8.3.1 North America Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
        • 8.3.1.1 North America Omics-Based Clinical Trials Market, by Country, 2025 - 2034 (USD Billion )
    • 8.4 North America Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034
      • 8.4.1 North America Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034 (USD Billion )
    • 8.5 North America Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034
      • 8.5.1 North America Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034 (USD Billion )
    • 8.6 North America Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034
      • 8.6.1 North America Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034 (USD Billion )
    • 8.4. Europe
      • 8.4.2 Europe Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
        • 8.4.2.1 Europe Omics-Based Clinical Trials Market, by Country, 2025 - 2034 (USD Billion )
    • 8.4 Europe Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034
      • 8.4.1 Europe Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034 (USD Billion )
    • 8.5 Europe Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034
      • 8.5.1 Europe Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034 (USD Billion )
    • 8.6 Europe Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034
      • 8.6.1 Europe Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034 (USD Billion )
    • 8.5. Asia Pacific
      • 8.5.3 Asia Pacific Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
        • 8.5.3.1 Asia Pacific Omics-Based Clinical Trials Market, by Country, 2025 - 2034 (USD Billion )
    • 8.4 Asia Pacific Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034
      • 8.4.1 Asia Pacific Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034 (USD Billion )
    • 8.5 Asia Pacific Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034
      • 8.5.1 Asia Pacific Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034 (USD Billion )
    • 8.6 Asia Pacific Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034
      • 8.6.1 Asia Pacific Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034 (USD Billion )
    • 8.6. Latin America
      • 8.6.4 Latin America Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
        • 8.6.4.1 Latin America Omics-Based Clinical Trials Market, by Country, 2025 - 2034 (USD Billion )
    • 8.4 Latin America Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034
      • 8.4.1 Latin America Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034 (USD Billion )
    • 8.5 Latin America Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034
      • 8.5.1 Latin America Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034 (USD Billion )
    • 8.6 Latin America Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034
      • 8.6.1 Latin America Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034 (USD Billion )
    • 8.7. The Middle-East and Africa
      • 8.7.5 The Middle-East and Africa Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
        • 8.7.5.1 The Middle-East and Africa Omics-Based Clinical Trials Market, by Country, 2025 - 2034 (USD Billion )
    • 8.4 The Middle-East and Africa Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034
      • 8.4.1 The Middle-East and Africa Omics-Based Clinical Trials Market, by Phase Type, 2025 - 2034 (USD Billion )
    • 8.5 The Middle-East and Africa Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034
      • 8.5.1 The Middle-East and Africa Omics-Based Clinical Trials Market, by Study Design Type, 2025 - 2034 (USD Billion )
    • 8.6 The Middle-East and Africa Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034
      • 8.6.1 The Middle-East and Africa Omics-Based Clinical Trials Market, by Indication Type, 2025 - 2034 (USD Billion )
  • Chapter 9. Company Profiles
    • 9.1 Novo Nordisk
      • 9.1.1 Overview
      • 9.1.2 Financials
      • 9.1.3 Product Portfolio
      • 9.1.4 Business Strategy
      • 9.1.5 Recent Developments
    • 9.2 Parexel International Corporation
      • 9.2.1 Overview
      • 9.2.2 Financials
      • 9.2.3 Product Portfolio
      • 9.2.4 Business Strategy
      • 9.2.5 Recent Developments
    • 9.3 GSK (GlaxoSmithKline)
      • 9.3.1 Overview
      • 9.3.2 Financials
      • 9.3.3 Product Portfolio
      • 9.3.4 Business Strategy
      • 9.3.5 Recent Developments
    • 9.4 Pharmaceutical Product Development (PPD)
      • 9.4.1 Overview
      • 9.4.2 Financials
      • 9.4.3 Product Portfolio
      • 9.4.4 Business Strategy
      • 9.4.5 Recent Developments
    • 9.5 Moderna
      • 9.5.1 Overview
      • 9.5.2 Financials
      • 9.5.3 Product Portfolio
      • 9.5.4 Business Strategy
      • 9.5.5 Recent Developments
    • 9.6 Charles River Laboratory
      • 9.6.1 Overview
      • 9.6.2 Financials
      • 9.6.3 Product Portfolio
      • 9.6.4 Business Strategy
      • 9.6.5 Recent Developments
    • 9.7 Freenome
      • 9.7.1 Overview
      • 9.7.2 Financials
      • 9.7.3 Product Portfolio
      • 9.7.4 Business Strategy
      • 9.7.5 Recent Developments
    • 9.8 Eli Lilly and Company
      • 9.8.1 Overview
      • 9.8.2 Financials
      • 9.8.3 Product Portfolio
      • 9.8.4 Business Strategy
      • 9.8.5 Recent Developments
    • 9.9 ICON plc
      • 9.9.1 Overview
      • 9.9.2 Financials
      • 9.9.3 Product Portfolio
      • 9.9.4 Business Strategy
      • 9.9.5 Recent Developments
    • 9.10 Genomics
      • 9.10.1 Overview
      • 9.10.2 Financials
      • 9.10.3 Product Portfolio
      • 9.10.4 Business Strategy
      • 9.10.5 Recent Developments
    • 9.11 Pfizer Inc.
      • 9.11.1 Overview
      • 9.11.2 Financials
      • 9.11.3 Product Portfolio
      • 9.11.4 Business Strategy
      • 9.11.5 Recent Developments
    • 9.12 BioNTech
      • 9.12.1 Overview
      • 9.12.2 Financials
      • 9.12.3 Product Portfolio
      • 9.12.4 Business Strategy
      • 9.12.5 Recent Developments
    • 9.13 SGS SA
      • 9.13.1 Overview
      • 9.13.2 Financials
      • 9.13.3 Product Portfolio
      • 9.13.4 Business Strategy
      • 9.13.5 Recent Developments
    • 9.14 Rebus Bio
      • 9.14.1 Overview
      • 9.14.2 Financials
      • 9.14.3 Product Portfolio
      • 9.14.4 Business Strategy
      • 9.14.5 Recent Developments
    • 9.15 Covance Inc.
      • 9.15.1 Overview
      • 9.15.2 Financials
      • 9.15.3 Product Portfolio
      • 9.15.4 Business Strategy
      • 9.15.5 Recent Developments
    • 9.16 and others.
      • 9.16.1 Overview
      • 9.16.2 Financials
      • 9.16.3 Product Portfolio
      • 9.16.4 Business Strategy
      • 9.16.5 Recent Developments

Table Of Figures

  • 1. Market research Type
  • 2. Market research methodology
  • 3. Global Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
  • 4. Porter’s Five Forces Analysis
  • 5. Global Omics-Based Clinical Trials Market attractiveness, By Phase Type
  • 6. Global Omics-Based Clinical Trials Market attractiveness, By Study Design Type
  • 7. Global Omics-Based Clinical Trials Market attractiveness, By Indication Type
  • 8. Global Omics-Based Clinical Trials Market share by Phase Type, 2025 and 2034 (USD Billion )
  • 9. Global Omics-Based Clinical Trials Market by Phase 1, 2025 - 2034 (USD Billion )
  • 10. Global Omics-Based Clinical Trials Market by Phase II, 2025 - 2034 (USD Billion )
  • 11. Global Omics-Based Clinical Trials Market by Phase III, 2025 - 2034 (USD Billion )
  • 12. Global Omics-Based Clinical Trials Market by Phase IV, 2025 - 2034 (USD Billion )
  • 13. Global Omics-Based Clinical Trials Market share by Study Design Type, 2025 and 2034 (USD Billion )
  • 14. Global Omics-Based Clinical Trials Market by Observational Studies, 2025 - 2034 (USD Billion )
  • 15. Global Omics-Based Clinical Trials Market by Interventional Studies, 2025 - 2034 (USD Billion )
  • 16. Global Omics-Based Clinical Trials Market by Expanded Access Studies, 2025 - 2034 (USD Billion )
  • 17. Global Omics-Based Clinical Trials Market share by Indication Type, 2025 and 2034 (USD Billion )
  • 18. Global Omics-Based Clinical Trials Market by Genetic Diseases, 2025 - 2034 (USD Billion )
  • 19. Global Omics-Based Clinical Trials Market by Respiratory Diseases, 2025 - 2034 (USD Billion )
  • 20. Global Omics-Based Clinical Trials Market by Oncology, 2025 - 2034 (USD Billion )
  • 21. Global Omics-Based Clinical Trials Market by Immunology, 2025 - 2034 (USD Billion )
  • 22. Global Omics-Based Clinical Trials Market by CNS Diseases, 2025 - 2034 (USD Billion )
  • 23. Global Omics-Based Clinical Trials Market by Skin Diseases, 2025 - 2034 (USD Billion )
  • 24. Global Omics-Based Clinical Trials Market by Others, 2025 - 2034 (USD Billion )
  • 25. Global Omics-Based Clinical Trials Market share, by Region, 2025 and 2034
  • 26. North America Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
  • 27. Europe Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
  • 28. Asia Pacific Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
  • 29. Latin America Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )
  • 30. The Middle-East and Africa Omics-Based Clinical Trials Market, 2025 - 2034 (USD Billion )

Table Of Tables

  • 1. Global Omics-Based Clinical Trials Market: Snapshot
  • 2. Drivers of the Omics-Based Clinical Trials Market: impact analysis
  • 3. North America Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 4. North America Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 5. North America Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 6. U.S. Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 7. U.S. Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 8. U.S. Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 9. Canada Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 10. Canada Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 11. Canada Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 12. Europe Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 13. Europe Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 14. Europe Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 15. Germany Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 16. Germany Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 17. Germany Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 18. France Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 19. France Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 20. France Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 21. U.K. Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 22. U.K. Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 23. U.K. Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 24. Italy Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 25. Italy Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 26. Italy Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 27. Spain Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 28. Spain Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 29. Spain Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 30. Rest of Europe Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 31. Rest of Europe Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 32. Rest of Europe Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 33. Asia Pacific Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 34. Asia Pacific Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 35. Asia Pacific Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 36. China Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 37. China Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 38. China Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 39. Japan Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 40. Japan Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 41. Japan Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 42. India Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 43. India Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 44. India Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 45. South Korea Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 46. South Korea Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 47. South Korea Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 48. South-East Asia Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 49. South-East Asia Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 50. South-East Asia Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 51. Rest of Asia Pacific Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 52. Rest of Asia Pacific Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 53. Rest of Asia Pacific Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 54. Latin America Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 55. Latin America Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 56. Latin America Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 57. Brazil Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 58. Brazil Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 59. Brazil Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 60. Mexico Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 61. Mexico Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 62. Mexico Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 63. Rest of Latin America Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 64. Rest of Latin America Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 65. Rest of Latin America Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 66. The Middle-East and Africa Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 67. The Middle-East and Africa Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 68. The Middle-East and Africa Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 69. GCC Countries Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 70. GCC Countries Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 71. GCC Countries Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 72. South Africa Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 73. South Africa Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 74. South Africa Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )
  • 75. Rest of Middle-East Africa Omics-Based Clinical Trials Market revenue, By Phase Type, 2025 - 2034 (USD Billion )
  • 76. Rest of Middle-East Africa Omics-Based Clinical Trials Market revenue, By Study Design Type, 2025 - 2034 (USD Billion )
  • 77. Rest of Middle-East Africa Omics-Based Clinical Trials Market revenue, By Indication Type, 2025 - 2034 (USD Billion )

Methodology

FrequentlyAsked Questions

Omics-based clinical trials aim to deliver highly personalized medical treatment by studying a patient’s proteomics, transcriptomics, and genomics.

The global omics-based clinical trials market is projected to grow due to the rising demand for improved cancer detection solutions and treatment strategies.

According to study, the global omics-based clinical trials market size was worth around USD 6.46 billion in 2024 and is predicted to grow to around USD 13.56 billion by 2034.

The CAGR value of the omics-based clinical trials market is expected to be around 7.70% during 2025-2034.

The global omics-based clinical trials market is projected to be led by North America during the forecast period.

The global omics-based clinical trials market is led by players like Novo Nordisk, Parexel International Corporation, GSK (GlaxoSmithKline), Pharmaceutical Product Development (PPD), Moderna, Charles River Laboratory, Freenome, Eli Lilly and Company, ICON plc, Genomics, Pfizer Inc., BioNTech, SGS SA, Rebus Bio, and Covance Inc.

The report explores crucial aspects of the omics-based clinical trials market, including a detailed discussion of existing growth factors and restraints, while browsing future growth opportunities and challenges that impact the market.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

twitter

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed